Skip to main content
TipRanks
Go Ultimate75% OFF

AlzeCure Pharma AB (AC6) AI Stock Analysis

3 Followers
DE:AC6

AlzeCure Pharma AB

(Frankfurt:AC6)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageLow leverage gives AlzeCure more balance-sheet flexibility than a highly indebted development-stage biotech. With debt materially below equity, the company has less interest burden and fewer debt-related constraints while it advances its pipeline and seeks external funding or partners.
Negative Factors
No Commercial RevenueZero reported revenue means AlzeCure has not yet established a commercial earnings base to offset research and development spending. Persistent losses, including a TTM net loss of about 59.2M, leave near-term performance dependent on pipeline progress rather than recurring operating income.

AlzeCure Pharma AB (AC6) vs. iShares MSCI Germany ETF (EWG)

-100%0%100%200%300%400%DE:AC6+240.13%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 76.33M
Dividend Yield
―
Average Volume (3M)
1,354
Price to Earnings (P/E)
10.2
Beta (1Y)
-0.39
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
10
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

AlzeCure Pharma AB Business Overview & Revenue Model

Company Description

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates base...

AlzeCure Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:AC6 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CAMXSE:CAMX78OutperformSEK 44.36B57.6816.50%―2.96%-4.07%
SE:SANIONSE:SANION77OutperformSEK 1.59B8.6029.71%―24.98%-31.44%
SE:BIOA.BSE:BIOA.B65NeutralSEK 27.01B255.805.18%0.71%-46.09%-90.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IRLAB.ASE:IRLAB.A37UnderperformSEK 116.89M-1.56-75.46%―-21.20%68.24%
SE:ALZSE:ALZ36UnderperformSEK 100.66M-1.88-15.44%―-100.00%40.79%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%DE:AC6SE:CAMXSE:ALZSE:BIOA.BSE:SANIONSE:IRLAB.ADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:AC6 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:AC6AlzeCure Pharma AB0.530.38240.13%
SE:CAMXCamurus AB732.50118.0019.20%
SE:ALZAlzinova AB0.32-1.14-78.11%
SE:BIOA.BBioArctic AB Class B304.4021.687.67%
SE:SANIONSaniona AB11.53-5.39-31.86%
SE:IRLAB.AIRLAB Therapeutics AB Class A0.78-1.23-61.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.